EXEL catalyst calendar

EXELIXIS, INC.

Upcoming catalysts
14
Cash runway
Cash generating
Cash & investments
$839M
Phase 3 programs
11

EXELIXIS, INC. is tracked here for clinical trial milestones, SEC filings and earnings dates. Focus area: Biological Products, (No Diagnostic Substances).

The next scheduled catalyst is Next quarterly earnings (projected) on October 28, 2026, a projected date rather than a confirmed one. There are 14 upcoming events on record.

EXELIXIS, INC. generates cash from operations, so a burn-based runway figure does not apply.

Across 33 concluded trials, 55% reached completion rather than being terminated or withdrawn.

Upcoming catalysts

DateEventTypePhase
October 28, 2026 est. Next quarterly earnings (projected) Earnings —
November 23, 2026 Study of XB010 in Subjects With Solid Tumors Trial Milestone Phase 1
December 15, 2026 Study of XL092 + Nivolumab vs Sunitinib in Subjects With Advanced or Metastatic Non-Clear Cell Renal Cell Carcinoma Trial Milestone Phase 3
January 31, 2027 Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors Trial Milestone Phase 1
May 31, 2027 A Study of XB628 Alone and in Combination With Zanzalintinib in Participants With Recurrent Advanced or Metastatic Solid Tumors Trial Milestone Phase 1
November 15, 2027 A Study of XB371 Administered in Participants With Locally Advanced or Metastatic Solid Tumors Trial Milestone Phase 1
February 29, 2028 A Study of Zanzalintinib in Participants With Recurrent or Progressive Meningioma Trial Milestone Phase 2
June 15, 2028 Zanzalintinib and Pembrolizumab in First-Line Maintenance for Metastatic Squamous Non-Small Cell Lung Cancer (NSCLC) Trial Milestone Phase 2
July 31, 2028 Study of Zanzalintinib in Children and Adolescents With Relapsed or Refractory Solid Tumors Trial Milestone Phase 1
August 15, 2028 Study of Zanzalintinib (XL092) + Pembrolizumab vs Pembrolizumab in Subjects With PD-L1 Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Trial Milestone Phase 2/Phase 3
January 3, 2029 A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Participants With Advanced Solid Tumors Trial Milestone Phase 1
June 30, 2029 Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors Trial Milestone Phase 2/Phase 3
April 5, 2030 Zanzalintinib Alone or in Combination With Pembrolizumab and Berahyaluronidase Alfa in Participants With Colorectal Cancer With Molecular Residual Disease Trial Milestone Phase 3
May 31, 2030 Long-Term Extension Study for Participants Previously Enrolled in an Exelixis-Sponsored Study Trial Milestone Phase 3

Track EXEL alongside other companies. Add it to a watchlist and see every catalyst on one calendar.

Open EXEL in the tracker

Recent history

DateEventTypePhase
September 11, 2026 8-K filed: Other event Filing —
August 31, 2026 8-K filed: Other event Filing —
August 31, 2026 A Study of XL092 as Single-Agent and Combination Therapy in Subjects With Solid Tumors Trial Milestone Phase 1
August 5, 2026 Quarterly results filed (8-K) Earnings —
June 16, 2026 Study of XL092 + Atezolizumab vs Regorafenib in Participants With Metastatic Colorectal Cancer Trial Milestone Phase 3
May 29, 2026 8-K filed: Leadership change Corporate —
May 5, 2026 Quarterly results filed (8-K) Earnings —
February 10, 2026 Quarterly results filed (8-K) Earnings —
January 12, 2026 Quarterly results filed (8-K) Earnings —
December 15, 2025 Pharmacokinetics (PK) and Safety of Zanzalintinib in Participants With Moderate Hepatic Impairment (HI) Trial Milestone Phase 1
November 7, 2025 8-K filed: Leadership change, Other event Corporate —
November 4, 2025 Quarterly results filed (8-K) Earnings —
August 29, 2025 8-K filed: Leadership change Corporate —
July 28, 2025 Quarterly results filed (8-K) Earnings —
May 13, 2025 Quarterly results filed (8-K) Earnings —
May 12, 2025 Study of Zanzalintinib (XL092) + AB521 and Zanzalintinib + AB521 + Nivolumab in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC) or Other Advanced Solid Tumors (STELLAR-009) Trial Milestone Phase 1
May 7, 2025 A Dose-escalation, Dose-finding, and Expansion Study of XL495 in Participants With Locally Advanced or Metastatic Solid Tumors Trial Milestone Phase 1
March 10, 2025 Study of XB002 in Subjects With Solid Tumors (JEWEL-101) Trial Milestone Phase 1
May 2, 2024 Study of XL102 as Single-Agent and Combination Therapy in Subjects With Solid Tumors (QUARTZ-101) Trial Milestone Phase 1
April 19, 2024 Study of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Subjects With mCRPC Trial Milestone Phase 3
February 21, 2023 Study of Cabozantinib Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors Trial Milestone Phase 1
November 1, 2022 Study of XL114 in Subjects With Non-Hodgkin's Lymphoma Trial Milestone Phase 1
January 31, 2022 Study of Cabozantinib in Combination With Nivolumab and Ipilimumab in Patients With Previously Untreated Advanced or Metastatic Renal Cell Carcinoma Trial Milestone Phase 3
November 30, 2021 Study of Cabozantinib in Combination With Atezolizumab Versus Sorafenib in Participants With Advanced Hepatocellular Carcinoma (HCC) Who Have Not Received Previous Systemic Anticancer Therapy Trial Milestone Phase 3
August 19, 2020 A Study of Cabozantinib Compared With Placebo in Subjects With Radioiodine-refractory Differentiated Thyroid Cancer Who Have Progressed After Prior Vascular Endothelial Growth Factor Receptor (VEGFR) -Targeted Therapy Trial Milestone Phase 3
July 15, 2020 A Study of Two Different Doses of Cabozantinib (XL184) in Progressive, Metastatic Medullary Thyroid Cancer Trial Milestone Phase 4
October 16, 2017 Study of Cabozantinib (XL184) vs Placebo in Subjects With Hepatocellular Carcinoma Who Have Received Prior Sorafenib Trial Milestone Phase 3

About this data

Trial milestones come from the ClinicalTrials.gov v2 API, filings from SEC EDGAR, and financial figures from SEC XBRL company facts. Dates marked est. are projected rather than company-confirmed. This is an information tool, not investment advice — verify anything you act on against the linked primary source.

Last updated 2026-10-14.